Validation of pediatric Functional Assessment of Cancer Therapy: patient version 2 of "brain tumor survivor" for grade school patients aged 7-12 years.

Heejung Yoo*, Young Shin Ra, Hyeon Jin Park, Jin Shei Lai, David Cella, Hee Young Shin, Dong Seok Kim, Woo Chul Kim, Yong Soon Shin

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

We evaluated the reliability and validity of the Pediatric Functional Assessment of Cancer Therapy-Childhood Brain Tumor Survivor version 2.0 (pedsFACT-BrS; patient version for grade school children aged 7-12 years). After translating and cross-culturally adapting it into Korean, the psychometric properties of the pedsFACT-BrS were evaluated in 148 childhood brain tumor survivors (mean age, 9.67 years). Pre-testing was performed in 25 patients. The pedsFACT-BrS showed good symptom coverage and overall user comprehension. Internal consistency was acceptable, with Cronbach's α coefficients ranging from 0.70 to 0.92. The pedsFACT-BrS also demonstrated good convergent and divergent validities when correlated with the Revised Children's Manifest Anxiety Scale and Kovacs' Children's Depression Scale. The pedsFACT-BrS showed good known-group validity and effectively differentiated between clinically distinct patient groups (patient vs. control groups, and among patients having different Karnofsky scores), but offered only partial discrimination of physical well-being (PWB) scores when patients were grouped by treatment type. Our results indicate that this instrument is reliable and valid and can be used to evaluate the quality of life of Korean childhood brain tumor survivors.

Original languageEnglish (US)
Pages (from-to)529-535
Number of pages7
JournalQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Volume20
Issue number4
DOIs
StatePublished - May 1 2011

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Validation of pediatric Functional Assessment of Cancer Therapy: patient version 2 of "brain tumor survivor" for grade school patients aged 7-12 years.'. Together they form a unique fingerprint.

  • Cite this